ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once-daily pill for plaque psoriasis [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Nearly 60% of adolescents treated with ICOTYDE achieved completely clear skin at Week 52 in the ICONIC-LEAD study SPRING HOUSE, Pa. March 28, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies, which assessed the efficacy and safety of ICOTYDE™ (icotrokinra) in the treatment of patients with moderate-to-severe plaque psoriasis (PsO). ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor. These data are being presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting. (PRNewsfoto/Johnson & Johnson) ICOTYDE achieved high levels of complete skin clearance up to Week 52 with no new safety signals ,a In the ICOTYDE treatment arms, rates of completely clear skin (PASI 100) increased from 41% to 49% and 33% to 48% from Week 24 to Week 52 in ADVANCE 1 and 2, respectively. a,b Patients who switched from placebo to ICOTYDE a
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson & Johnson (JNJ) had its "outperform" rating reaffirmed by Royal Bank Of Canada. They now have a $255.00 price target on the stock.MarketBeat
- The Low-Volatility Promise of ACWV Costs Investors 118% Over a Decade Compared to SPY [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases [Yahoo! Finance]Yahoo! Finance
- AtaiBeckley Weighs BPL-003 Deal After Strong Phase 2a And FDA Support [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson Oncology And Immunology Advances Test Valuation Story [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/18/26 - Form 13F-HR/A
- 3/18/26 - Form 13F-HR/A
- JNJ's page on the SEC website